24 November, 2020
Capital Markets Day
The virtual Capital Markets Day consisted of presentations from Active Biotech executives and international experts. This was followed by a live Q&A webcast. Links to the presentations are found further down on this page.
A replay of the live webcast can be seen in the player below.
Presentations
Welcome and Introduction
Laquinimod – Treatment of Inflammatory Eye Disorders
Tasquinimod – Treatment of Multiple Myeloma
An Introduction to Multiple Myeloma
A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma
Naptumomab – Next generation immunotherapy capable of targeting cold tumors
Presenters
Helén Tuvesson
CEO
Helén has a Ph.D in cell and molecular biology in Medical Science and more than 25 years of experience in leading drug development in senior positions.
Helena Eriksson
CSO
Helena has a Ph.D in experimental hematology in Medical Science and has more than 25 years of experience in the pharmaceutical industry.
Axel Glasmacher
Dr. med.
Adjunct professor of medicine at the University of Bonn, Germany.
Previous Head of Global Clinical R&D and Senior Vice President for Celgene.
Member of the Board at Active Biotech
Dan Vogl
MD, MSCE
Director, Abramson Cancer Center Clinical Research Unit and Associate Professor of Medicine at the University of Pennsylvania, US.
Principal Investigator Phase 1b/2a clinical study with Tasquinimod.
Asher Nathan
CEO NeoTX
Asher is the CEO of Neotx Therapeutics, a clinical stage immunotherapy company. Since 2016, Active Biotech has a license agreement with NeoTX for the global development and commercialization of naptumomab for cancer treatment.